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Abstract
Background: Treatments for uncomplicated falciparum malaria should have high cure rates. The
World Health Organization has recently set a target cure rate of 95% assessed at 28 days. The use
of more effective drugs, with longer periods of patient follow-up, and parasite genotyping to
distinguish recrudescence from reinfection raise issues related to the design and interpretation of
antimalarial treatment trials in uncomplicated falciparum malaria which are discussed here.
Methods:  The importance of adequate follow-up is presented and the advantages and
disadvantages of non-inferiority trials are discussed. The different methods of interpreting trial
results are described, and the difficulties created by loss to follow-up and missing or indeterminate
genotyping results are reviewed.
Conclusion: To characterize cure rates adequately assessment of antimalarial drug efficacy in
uncomplicated malaria requires a minimum of 28 days and as much as 63 days follow-up after
starting treatment. The longer the duration of follow-up in community-based assessments, the
greater is the risk that this will be incomplete, and in endemic areas, the greater is the probability
of reinfection. Recrudescence can be distinguished from reinfection using PCR genotyping but
there are commonly missing or indeterminate results. There is no consensus on how these data
should be analysed, and so a variety of approaches have been employed. It is argued that the correct
approach to analysing antimalarial drug efficacy assessments is survival analysis, and patients with
missing or indeterminate PCR results should either be censored from the analysis, or if there are
sufficient data, results should be adjusted based on the identified ratio of new infections to
recrudescences at the time of recurrent parasitaemia. Where the estimated cure rates with
currently recommended treatments exceed 95%, individual comparisons with new regimens should
generally be designed as non-inferiority trials with sample sizes sufficient to determine adequate
precision of cure rate estimates (such that the lower 95% confidence interval bound exceeds 90%).
Background
For a patient ill with malaria, rapid resolution of illness
without complications from the disease or its treatment is
the first priority. Preventing return of the illness is a sec-
ond priority. In a high transmission setting reinfection is
inevitable, so the longer that subsequent illness can be
delayed, the better. Those who deploy antimalarial drugs
have similar objectives, but need to know more. In partic-
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ular they need to know the efficacy of the individual treat-
ment against the parasites which caused the infection. The
key measure is the cure rate. The cure rate is defined as the
proportion of treated patients whose symptoms resolve,
parasitaemia becomes undetectable and in whom there
are no recrudescences of infection with the genotypes
which caused the original illness. This review discusses
how the cure rate should be measured and reported.
The treatment of malaria is changing for the better, but
this has brought new challenges in the design and inter-
pretation of efficacy assessments. In the past few years, it
has become accepted that antimalarial treatments must
have high cure rates, which ideally should exceed 90% [1].
The corollary that malaria treatment recommendations
should change if cure rates are below 90% requires further
definition, but this is a considerable advance on the previ-
ous era when much lower rates were considered accepta-
ble, and there was often no reliable information on the
cure rates with chloroquine or sulfadoxine-pyrimeth-
amine (by far the most widely used antimalarial drugs). In
this earlier context of uncertainty it was reasonable to plan
a randomized comparison to test if there was a difference
between the regimens being tested (a "superiority" trial).
But now better antimalarial drugs exist, and much more
information is available about them [2], and thus there is
greater a-priori certainty of high cure rates with currently
recommended treatments. So as cure rates with current
treatments approach 100%, differences between treat-
ment regimens are progressively harder to detect. The con-
ventional "superiority" trial cannot show that a new drug
is better. Alternative test strategies are required for evalu-
ating new treatments. Well-conducted, randomized com-
parative trials are still preferable to single-arm,
observational studies as they confirm or refute a-priori
estimates of efficacy, reduce investigator biases, and
account for systematic errors. Equivalence trials, in which
an attempt is made to prove that two (or more) treatments
are the same, are unnecessary. The preferable alternative is
a "non-inferiority trial", which tests the hypothesis that
the new treatment is not significantly worse than the cur-
rent treatment. It is up to the investigator or current opin-
ion to define the bounds of "significantly worse". But this
approach requires different sample size calculations and
has certain limitations which will be discussed.
The efficacy of antimalarial drug treatment, in uncompli-
cated falciparum malaria is assessed by following patients
after observed treatment for sufficient time to "capture"
all or most of the treatment failures (failures to cure the
infection leading to recrudescences) that could occur. As
recrudescences result from persistent erythrocytic infec-
tion, these recurrent infections re-emerge within a defined
time period following treatment [3,4]. This period is
dependent mainly on the susceptibility of the infection
and the elimination kinetics of the antimalarial treatment.
Following treatment with rapidly eliminated drugs most
recrudescences occur within four weeks, but following
treatment with slowly eliminated antimalarial drugs the
recrudescences may be delayed, and so longer follow-up is
needed to capture them, otherwise failure rates will be
underestimated [5]. Recrudescences more than nine
weeks after any treatment are unusual. For this reason, if a
rapidly eliminated treatment is compared with a slowly
eliminated treatment, and follow-up is only 28 days, the
results tend to be biased in favour of the slowly eliminated
treatment. Recent studies have characterized the relation-
ship between time to recrudescence and the pharmacoki-
netic properties of the antimalarial drug treatment, and
have provided evidence-based recommendations for the
duration of follow-up; 63 days follow-up is recom-
mended for slowly eliminated drugs (t1/2 > 1 week e.g.
mefloquine, piperaquine) and a 28-day follow-up is the
minimum for rapidly eliminated antimalarial drugs [6].
For drugs with intermediate elimination half-lives (t1/2 is
1 day to 1 week) 42 days follow-up captures most of the
recrudescences. WHO now recommends a minimum of
28 days follow-up in antimalarial drug in-vivo studies.
[7]. As increasingly higher cure rates are demanded of new
antimalarial treatments, true cure rate must be defined or
estimated with better precision. This has important impli-
cations for the design of antimalarial drug trials.
Conducting large trials with extended patient follow-up is
logistically demanding. In endemic areas it is not possible
clinically to distinguish a recrudescence from a newly
acquired infection (or, in the case of Plasmodium vivax and
Plasmodium ovale infections, a relapse). The use of PCR
genotyping of Plasmodium falciparum has considerably
improved the ability to conduct community-based clini-
cal trials of antimalarial drugs in endemic areas [8,9].
Unfortunately assessment of treatment responses in P.
vivax malaria is more difficult as recurrence of the infec-
tion may result from recrudescence, reinfection or relapse.
The relapses derive from persistent hypnozoites in the
liver and are commonly with different genotypes to that
identified in the acute infection [10,11]. Assessment in
vivax malaria will be subject of a separate review. In P. fal-
ciparum studies blood samples are taken, usually on filter
paper, and the genotypes are compared in blood samples
from the acute infection and any infection which recurs
during the period of follow-up. P. falciparum genotyping
is usually based on comparison of variable blocks within
the polymorphic genes MSP1, MSP2, and also often
GLURP, or by use of microsatellite typing. Sometimes
blood samples from the recurrent infection or the acute
infection are not available, or go missing, or there are
technical reasons while the PCR comparison cannot take
place. In higher transmission settings a genotype often
cannot be ascribed confidently in multiple infections (i.e.Malaria Journal 2006, 5:127 http://www.malariajournal.com/content/5/1/127
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there is patent infection with several different genotypes).
How should these patients then be evaluated? There is no
clear consensus – but calling all missing or indeterminate
results treatment failures is clearly illogical. Ideally in a
study, all participants in the trial should complete the
study, follow the protocol, and provide data on all the
outcomes of interest at all time-points. In reality, most tri-
als have missing data. Data can be missing either because
critical information, such as PCR genotyping, is missing
or uninterpretable [12], or because some of the partici-
pants drop out (i.e. fail to attend for the follow-up
appointments) before the end of the trial. This risk
increases with longer follow-up periods, long after
patients have finished treatment and benefited from it.
Patients with missing data are often considered conserva-
tively as therapeutic failures (an "intention to treat" or
"ITT" approach), but with highly efficacious treatments as
failure rates approach zero, missing data may comprise
the majority of "therapeutic failures" thereby distorting
considerably the assessment of efficacy. In this review
some suggestions (with formulae and worked examples)
are presented for the design of antimalarial drug trials and
the analysis of incomplete data.
Failure data are "survival" data
In antimalarial drug trials there are two or more groups of
patients followed for a prespecified length of time after
different antimalarial treatments. The cure rates, which
means the proportions of patients who reach the end of
this follow-up period without recrudescence of the infec-
tion are compared. In the past, antimalarial treatment effi-
cacy was usually assessed on a particular day (often day 14
or day 28 after starting treatment) so only patients fol-
lowed to that day were included in the analysis. This is
often referred as a "per-protocol" (PP) analysis. But in most
trials there are patients who do not complete the follow-
up period, yet these patients do contribute useful infor-
mation before they leave the trial, and this can and should
be used. If such a patient did not fail (i.e. remained apar-
asitaemic) when last observed, that patient's data are said
to be 'censored' at the time they were last followed up. The
appropriate analysis for such data is survival analysis. This
analytical approach is well established in the assessment
of cancer chemotherapy and increasingly in the assess-
ment of anti-infective drugs, as survival analysis deals
explicitly with censored values. Patients with different fol-
low-up periods cannot be treated the same way – some-
one who is followed up for longer has a greater chance of
being recorded as treatment failure than another patient
followed up for a shorter time. Failure rates should be esti-
mated using the Kaplan-Meier method [13]. This is now
endorsed by the recent WHO recommendations for anti-
malarial resistance monitoring which suggest use of life
tables (i.e. survival analysis) in analysing in-vivo studies
[7].
Estimation of failure rates
The proportion of subjects beyond any follow-up time t
who have not developed a recrudescence is estimated by
the Kaplan-Meier method as
p = ∏ (ri-di)/ri
where ri is the number of subjects without a recrudescence
just before time ti, di denotes the number who had a recru-
descence at time ti and ∏ represents the product of all the
estimates at each time point ti until time t.
This proportion is equivalent to the efficacy of the treat-
ment and 1-p is equivalent to the failure rate of the treat-
ment.
The following example illustrates how analysis of categor-
ical data at defined end-points leads to errors when
patients are lost to follow-up and how this is best dealt
with by survival analysis.
Example
In a study of an antimalarial drug, follow-up was for 63
days. 100 patients were enrolled, and all of them were
evaluated at 28 days, but thereafter only 60 were observed
at each appointment until day 63. At day 28, 21 failures
were observed (and these patients were therefore not fol-
lowed further), an additional four failures were recorded
at day 63, and 19 patients were lost to follow-up between
days 28 and 63.
Estimation of the failure rate at day 28 is easy and equals
21/100 = 0.21.
What is the day 63 failure rate?
If all patients had been followed up until day 63 then the
failure rate would have been 0.25 (25/100), but it was not
the case.
In total 25 failures were observed but patients were fol-
lowed up for different periods of time. An analysis done
only on patients who completed the follow-up would
have a denominator of only 60 as the early failures (N =
21) and the patients lost to follow-up (N = 19) are not
included. It is obviously wrong to ignore these early fail-
ures, but if they are included in the analysis it assumes that
patients excluded (i.e. the 19 lost to follow-up) had the
same probability of failing during the entire follow-up
period as those included, whereas those lost to follow-up
did not fail in the period between 0 and 28 days (when 21
of the 25 observed failures did occur). The failure rate
would be estimated as:
25/(60 + 21) = 25/81 = 0.31   (A)Malaria Journal 2006, 5:127 http://www.malariajournal.com/content/5/1/127
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The correct analysis is based on the Kaplan-Meier
approach which incorporates these temporal changes in
the probability of failing treatment.
In the example, the failure rate at 28 days is 21/100, so the
probability of not failing during 28 days is 1-(21/100) or
0.79.
The 60 patients who did not fail until day 28 were fol-
lowed up until day 63, and for them the probability of
failing between day 28 and day 63 is 4/60 or 0.0667. Thus,
the probability of not failing between days 28 and 63 is 1-
0.0667 or 0.933.
Of course patients can only not fail in the second interval
(28–63 days) if they did not fail in the first interval (0–28
days). Therefore, the probability of not failing during 63
days is equal to the product of the probability of not fail-
ing during 0 to 28 days and the probability of not failing
between 29 and 63 days. This product is the treatment
success rate and the failure rate is one minus the success
rate.
So the failure rate is estimated as :
1-(1–21/100)*(1–4/60) = 0.27   (B)
This estimate is significantly lower than the per-protocol
estimate. Splitting follow-up into intervals and calculating
failure rates for these intervals makes sense biologically.
Recrudescences do not have the same probability of
occurring across the entire period of follow-up.
Figure 1 compares the per protocol estimate A (PP) of the
failure rate and the Kaplan-Meier estimate B (KM) for dif-
ferent numbers of patients dropping out from trial follow-
up after day 28 and different distributions of observed
failures. It is assumed that 100 patients were followed up
until day 28, and 20 failures were observed in total. The x-
axis represents the percentage of patients who dropped
out after day 28. Three scenarios are considered: (a) the
observed failures were equally spaced in time, 10 before
and 10 after day 28; (b) more failures (n = 18) occurred
before day 28; (c) more failures (n = 18) occurred after day
28.
For all three distributions of observed failures, the PP rate
estimate is the same, but the KM estimate varies. The dis-
crepancies between the two methods are greatest when
most of the observed failures occurred before patients
were lost to follow-up. Discrepancies also increase dra-
matically with the proportion of patients lost to follow-
up. Guthmann et al have recently reported a comparison
of per protocol and survival analysis [14] in 13 paediatric
studies conducted in sub-Saharan Africa. Only 6% of
patients data were lost with the KM survival analysis, com-
pared with 25% with the PP analysis. In high transmission
settings, or where mixed infections with P. vivax are com-
mon, a very high proportion of patients may have a recur-
rent infection within the follow-up period and be lost to a
PP analysis [12].
Assessment of confidence intervals
Statistical software used for the calculation of Kaplan-
Meier estimates will usually also provide confidence inter-
vals; these will be Greenwood's confidence intervals or
confidence intervals based on the asymptotic variance of -
log-log transformation of the survival function [15]. How-
ever it should be kept in mind that Greenwood's method
underestimates the variance of the Kaplan-Meier estimate.
Alternatively the confidence intervals can be calculated
using the effective sample size suggested by Peto [13].
'Effective' sample size at time ti will be equal to the total
number of patients when there are no censored observa-
tions, that is when all patients were followed until the
recurrence or time ti. When there are censored observa-
tions then the effective sample size at time ti is
Comparison of the effects of trial drop-outs on estimated  failure rates in 100 patients followed for 63 days after a treat- ment with a true 20% failure rate Figure 1
Comparison of the effects of trial drop-outs on estimated 
failure rates in 100 patients followed for 63 days after a treat-
ment with a true 20% failure rate. The "per protocol" 
method (PP), of estimating cure rates in which the denomina-
tor at each time point is the combined number of patients 
who were followed until that point and continued to be apar-
asitaemic and those who had a recrudescence observed, is 
shown as a red solid line and compared with the Kaplan-
Meier survival method. The drop-outs all occurred after 28 
days of follow-up. Three different scenarios are presented 
with differing proportions of failures (20 in total) presenting 
before and after 28 days: blue dash line – 2 failures before 
and 18 after day 28; orange dash line – 10 failures before and 
10 failures after day 28; green dash line – 18 failures before 
and 2 failures after day 28.
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N' = (ri-di)/p;
where ri is the number of subjects without a recrudescence
just before time ti,
di denotes the number who had a recrudescence at time ti
and p is the Kaplan-Meier estimate of a proportion of
patients surviving without a recrudescence beyond point
ti.
If the failure rate is very small or zero, standard confidence
intervals for proportions based on a normal approxima-
tion are not appropriate [16,17] and should not be used.
Wilson's method [18] is recommended for small propor-
tions while the exact binomial method can be used for
zero values:
0 to 1-(á/2)1/N';
where á is a significance level and N' is the effective sam-
ple size. An Excel spreadsheet for calculating the confi-
dence intervals for proportions and their differences is
freely available on the web [19].
Comparing the treatment groups
The simplest way of comparing and presenting the failure
rates and failure times between the treatment groups is to
plot the Kaplan-Meier survival estimates on the same axes.
To distinguish between chance variation in failure rate
estimates in the two groups and a real difference, a hypo-
thesis test is required. For survival data, two tests are com-
monly used: the log-rank test and the Wilcoxon test. Both
test the null hypothesis that there are no real differences
between the two groups, so small values of the test statis-
tics will correspond to the acceptance of the null hypo-
thesis. Both are based on the sum of the differences
between the observed and expected number of failures in
each group over all time points, but in the Wilcoxon test
this sum is weighted by the total number of individuals at
risk at each time. The log-rank test is preferable when the
Kaplan-Meier plots for the two groups do not cross, as this
reflects a continuous proportional difference in failure
rates between the two groups. If the survival curves do
cross, the Wilcoxon test should be used.
It is always useful to express the difference between the
two treatment groups in a summary measure. As the risk
of failure changes over time and the rates of change are
usually different in the two treatment groups, only meas-
ures evaluated at a prespecified timepoint are recom-
mended. These could be the absolute risk reduction or the
risk ratio (or relative risk). Hazard ratios [20], which are
commonly used in cancer treatment studies are usually
not relevant to malaria drug studies as they are assumed
to be constant across time.
The absolute risk reduction is the difference between fail-
ure rates in the two treatment groups. The risk ratio (rela-
tive risk) is calculated as the ratio of those failure rates. In
antimalarial trials, because of losses to follow-up, Kaplan
Meier estimates of failure rates should always be used. The
absolute risk reduction assesses the clinical importance of
the treatment difference while the relative risk has the
intuitive appeal as it measures the magnitude of the differ-
ence.
However, there are pitfalls in using the relative risks – for
uncommon events, large relative risks will result from dif-
ferences of only a few failures between the treatments, for
example 2% difference in failure rate between 2 treat-
ments of efficacy rates of 97% and 99% gives relative risk
of 3.
Proving non-inferiority in antimalarial drug comparisons
In the past antimalarial drug trials have been powered to
detect differences between drugs – usually with 95% con-
fidence and 80% power. This is increasingly difficult at
cure rates over 90% because of the exponential increase in
the sample size required (Figure 2). The higher the stand-
ard treatment's cure rate, the more difficult it is to demon-
strate conclusively a small difference in favour of a new
treatment. Characterizing a small difference in cure rates
(e.g. between 96% and 99%) is potentially important
(after all, this represents a four-fold difference in failure
rates) but it may not be logistically feasible. An alternative
approach is the non-inferiority trial. There is no clear
point at which superiority trials must give way to non-
inferiority trials. This depends on how the results of the
trial are to be used.
Non-inferiority trials aim to show that an experimental
treatment is not worse than the active control (i.e. current
treatment) by more than a specified amount – the equiv-
alence margin (often denoted δ). The null hypothesis
being tested is that there is a difference between the two
groups (i.e. it is the opposite to that in conventional supe-
riority trials) and it is greater than the δ. Rejection of the
null hypothesis indicates that there is no difference
between the groups. The choice of an appropriate value
for δ is a compromise based on current knowledge, clini-
cal judgement, likely policy implications and the practi-
calities of conducting large trials. Values of 10% have been
widely used in assessing antimicrobial agents, but are too
wide for current requirements for antimalarial drug effi-
cacy. Smaller equivalence margins require that studies
have larger sample sizes that have been usual in the past
[2]. Each comparison should be considered individually
[21,5]. There is a burgeoning statistical literature on the
limitations of non-inferiority trials, much of it recent [22-
24]. The main limitation from a statistical perspective is
that confounders introduced in a poorly conducted trialMalaria Journal 2006, 5:127 http://www.malariajournal.com/content/5/1/127
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which affect both groups, and are unrelated to differences
in the efficacy (or toxicity) of the trial regimens, can
obscure significant differences. In a superiority trial this
might lead to a failure to disprove the null hypothesis –
i.e. failure to show difference – but in a non-inferiority
trial the direction is opposite; a false rejection of the null
hypothesis and conclusion of non-inferiority [25]. This
emphasizes the importance in antimalarial drug trials of
avoiding errors in drug allocation and administration,
poor adherence, errors in end-point ascertainment (for
antimalarial efficacy this refers particularly to identifica-
tion of recrudescence), and loss to follow-up. These con-
siderations are particularly relevant to the choice of
analytical approach. The intention to treat (ITT)
approach, which is a robust, albeit conservative, method
of assessing superiority, is particularly vulnerable. It
should not be used as the primary endpoint for the assess-
ment of antimalarial drug efficacy when cure rates are
high.
Blinding is often used to avoid bias in comparative trials
although it is often difficult in antimalarial drug assess-
ments because of differences in treatment regimens and
the difficulties in masking the taste of the drugs. Com-
pared with superiority trials, blinding does not protect
against bias as well in non-inferiority trials because a
biased investigator wishing to show non-inferiority can
simply give all patients similar results! Analysis of non-
inferiority trials requires a calculation of the difference
between the failures rates in the treatment groups and a
calculation of the confidence interval around this differ-
ence using appropriate methods [26] and 'effective' sam-
ple sizes. An example is provided in the Appendix 1.
How should the results be reported?
Intention-to-treat (ITT) analysis intends to include all
patients randomized into the trial irrespective of what
happened to them subsequently [27,28]. This is straight-
forward if patients' outcomes have been evaluated and the
violation of the protocol was with respect to the received
treatment. But if their outcome is unknown there is no
clear consensus if patients should be still included in the
analysis [29], especially if their inclusion is only possible
after some imputation of the outcome is performed.
In the per protocol analysis (PP), on the other hand, drug
trial results are often analysed simply in categorical tables
comparing proportions of patients deemed to have been
cured at the predefined trial time-point(s). As explained
previously this ignores the contribution of information
provided by patients whose follow-up was incomplete.
The intention-to-treat analysis (ITT) analysis is widely
used to generate the most conservative estimate of the effi-
cacy of an antimalarial drug. In an ITT analysis all patients
who do not complete the follow-up period successfully
may be considered therapeutic failures. The results then
provide a combined assessment of the trial conduct and
the drug efficacies, with efficacy and follow-up failures
both having equal weight in the analysis. In antimalarial
drug trials with long follow-up drop-outs increase with
time. Thus, even if a drug has 100% true efficacy, an ITT
analysis will show progressively worse results as the dura-
tion of follow-up is extended. It is simply measuring loss
to follow-up and indeterminate or missing genotyping
results. Slowly eliminated drugs which require longer fol-
low-up will always fare worse. The better the drug is (ie.
the higher the true cure rate), the greater is the propor-
tional difference between true cure rate and ITT estimate.
This is illustrated in Figure 3. The ITT analysis should still
be done and reported to illustrate a "worst-case scenario"
but it should not be the primary endpoint in large com-
munity-based trials of antimalarial drug efficacy where
long follow-up is required and drop-outs likely.
Missing data problems
a) How should we deal with missing appointments?
Some patients miss a follow-up appointment and then
attend subsequently. These patients should not be cen-
sored from efficacy assessments if they have remained
well, as it is unlikely that a recrudescent malaria infection
would have occurred during the missed appointment
period which then rapidly and symptomlessly self-cured.
If the patient presents after the missing appointment with
The upper limit of two sided 95% confidence intervals for  single point estimates of failure rate for different sample  sizes, estimated using Wilson's method, are shown as solid  lines (upper left) Figure 2
The upper limit of two sided 95% confidence intervals for 
single point estimates of failure rate for different sample 
sizes, estimated using Wilson's method, are shown as solid 
lines (upper left). The upper limit of two sided 95% confi-
dence intervals for differences between the observed failure 
rate and a standard treatment with a failure rate of 5% for 
different sample sizes, estimated using Newcombe's method, 
are shown as dashed lines (lower right).
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a recrudescence then the history can be used to estimate
the onset of recrudescence. Continuous data (e.g. gameto-
cyte-time curves) present more of a problem, and these
need to be assessed on an individual basis. There may be
sufficient data to justify interpolation, or omission may be
appropriate.
b) Interpretation of indeterminate PCR genotyping results
The use of genotyping to distinguish reinfection from
recrudescence is based on the relative probabilities of
finding identical polymorphic malaria parasite alleles by
chance from the parasite population. It is necessary to
define these probabilities for each individual allele for the
parasite population (and thus patient population) under
study. For multiple alleles their individual distributions
must be unlinked. If there are multiple genotypes present
then qualitative assessments (without extensive sequenc-
ing) cannot ascribe an individual genotype, and although
probabilities can still be ascribed to recurrent infections,
statistical power is reduced. If a patient has a recurrent
infection in an antimalarial drug trial conducted in an
endemic area, but a paired sample is either unavailable or,
for technical reasons (no amplification, multiple bands
precluding a definitive result, etc.), a comparison of geno-
types cannot be made then a recrudescence (treatment
failure) cannot be distinguished from a newly acquired
infection. The interpretation of genotyping results in high
transmission settings, and the possibility that minority
(undetected) genotype populations may cause subse-
quent recrudescence is a subject of considerable interest
and debate. This is important subject and advances both
from a biological and statistical perspective can be
expected in the near future. But for the purpose of this dis-
cussion it is simply accepted that a potentially large
number of patients may have indeterminate results, and
that there is uncertainty as to how these patients should
be analysed.
To present the different analytical approaches, first it is
necessary to describe the following proportions:
At start of each interval (ti, ti+1, etc) there are ni, ni+1, etc.
patients at risk of having a recurrence of parasitaemia.
If during the interval from ti to ti+1 there were
ri patients with recrudescent infections,
ai patients with newly acquired patent infections,
ci patients without patent infections (i.e. aparasitaemic)
and
di patients who were lost to follow-up
then
ni = ri + ai + ci + di........................................................................................ (1)
Then ni+1 = ni - (ri+ ai +di) as those patients with true recru-
descences previously are no longer "at risk" (i.e. they can-
not have another recrudescence), and both dropouts and
those with new genotype infections are not followed up
further (the latter group having been treated).
The observed recurrences (ori) for whom genotyping
results are available will be either recrudescences, or new
infections, but for some of them the PCR results will be
indeterminate and so their status will not be known. If
indeterminate PCR genotyping results (ind) are unrelated
to treatment failure rates, and are not more or less likely
in recrudescences than in newly-acquired infections, then
they will occur at a constant rate (i.e. a constant propor-
tion (f) of the total recurrences with time):
indi = f·(ri + ai))...............................................................(2)
and subsequently ∑ indi = f·∑ (ri + ai)...........................(3)
In this notation, there are (1-f) ri confirmed recrudes-
cences and (1-f) ai confirmed new infections and so as ori
= ri + ai
Degree of overestimation of the true failure rate provided by  an ITT analysis where all patients failing to complete the trial  satisfactorily are considered as "treatment failures" Figure 3
Degree of overestimation of the true failure rate provided by 
an ITT analysis where all patients failing to complete the trial 
satisfactorily are considered as "treatment failures". Overes-
timation is calculated as a ratio of estimated failure rate using 
the ITT approach to the true failure rate. When true cure 
rates are low (i.e. less than 10% – vertical dotted line) the 
overestimation is considerable.
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then ori = (1-f) (ri + ai) + indi .........................................(4).
At each time interval, numbers ri and indi are small so esti-
mates of f may be inaccurate, and it may be better esti-
mated from the equation (3) using the total number of
indeterminate results and the total number of observed
recrudescences.
The ratio of recrudescences to new infections will depend
on the failure rate (which for new treatments should be
less than 10%), the malaria transmission intensity, and
time since the start of the treatment. In high-transmission
settings, eventually all patients will be reinfected. This and
the non-linear relationship between recrudescences and
reinfections (reflecting the relationship between a discrete
and a cumulative distribution) are illustrated in an exam-
ple which follows and in Figures 4a and 4b. But this
changing proportion of new infections and real recrudes-
cences does not affect the rate f. If f is only related to the
PCR technique and not malaria we would still have f·(ri +
ai) indeterminate results. So how should indeterminate
results be treated in the analysis of efficacy?
(i) Treating indeterminate results as failures (ITT or the worst-case 
scenario analysis)
In this approach all indeterminate PCR results are treated
as recrudescences (i.e. treatment failures).
i.e. the failure rate for interval (ti to ti+1) is:
FA = ((1-f)ri + indi)/(ni)
Unless there are no reinfections this method overesti-
mates the failure rate. This overestimation (proportion-
ally) is not so profound at high failure rates or at low
levels of malaria transmission, but, unless rates of indeter-
minate results are low, it creates serious discrepancies at
low failure rates in areas of medium to high transmission.
At its most extreme, if all patients are followed until they
acquire their next infection, then for a drug with 100%
efficacy (no true failures) the ITT failure rate equals the
rate of indeterminate PCR results. As this could well
exceed 10% then even a completely (100%) efficacious
antimalarial drug cannot achieve the level of >90% cure
rate currently recommended by the World Health Organ-
isation in the trial [1]. The effects of treating indetermi-
nate results as failures on the cure rate estimate are shown
in Tables 1 and 2. With increasing numbers of indetermi-
nate results the intention to treat analysis progressively
overestimates the true failure rate. The errors are propor-
tionately greatest at low failure rates. The ITT approach to
handling missing or inderminate PCR results is therefore
incorrect.
(ii) Treating indeterminate results as censored
In this approach no assumptions are made, and the
patients are simply censored from the analysis. They can
be censored at the time when the recurrent parasitaemia
occurred, that is at the end of the interval, at time ti+1.
FB = (1-f) ri/ni
Patients with the indeterminate results are treated in
exactly the same way as patients who became smear nega-
tive after treatment and were then lost to follow-up.
But as the PCR result is not known, and therefore whether
it is a recrudescence or reinfection cannot be determined,
the standard approach in survival analysis to the patient's
data would be to exclude them from the analysis in the
interval when the recurrence took place, so they have also
to be deducted from the number at risk ni at the beginning
of the interval.
FC = (1-f) ri/(ni-indi)
This corresponds to censoring them at the end of the pre-
vious interval, at time ti.
It could be argued that this type of censoring is not non-
informative but if the number of patients lost to follow-up
is small, very little bias is likely to result from applying
methods based on non-informative censoring [30].
(iii) Adjustment of the number of failures by the time adjusted rate 
of true failures derived from the valid PCR genotyping
This approach uses all the available data but relies on
there being sufficient data to characterize the temporal
changes in the probability of recurrent parasitaemia being
a recrudescence (gi) where gi is the proportion of recurrent
infections at time ti which are recrudescences. Thus at each
time point for a recurrent parasitaemia this probability of
recrudescence (gi) and a probability of reinfection (1-gi)
are determined for the study population from the valid
PCR-genotyping results. Obviously this requires sufficient
data for adequate characterization. This ratio of probabil-
ities is then applied to any indeterminate results.
FD = ori gi/ni = (ori·(1-f) ri/(ori - indi))/ni = FB/(1-f)
where gi = (1-f) ri/(ori - indi) is the proportion of recur-
rences with confirmed PCR results which are recrude-
cences at time ti.
Estimate FD is the most accurate provided we have a good
estimate of g.
Estimate FC is methodologically correct but its includes
patients with indeterminate results only while they didMalaria Journal 2006, 5:127 http://www.malariajournal.com/content/5/1/127
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a and b. Simulated example of a clinical trial evaluation of a slowly eliminated antimalarial drug (e.g. mefloquine) with a 23% fail- ure rate evaluated in an area with high malaria transmission (EIR 12/year) (upper panel) Figure 4
a and b. Simulated example of a clinical trial evaluation of a slowly eliminated antimalarial drug (e.g. mefloquine) with a 23% fail-
ure rate evaluated in an area with high malaria transmission (EIR 12/year) (upper panel). The apparent failure rate based on 
genotyping at 4 weeks is 3% and at 6 weeks is 15%. All patients are eventually reinfected once the drug has been eliminated and 
the prophylactic effect exhausted. There is a non-linear relationship between recrudescences and reinfections. Figure 4b shows 
the proportion of recurrent infections that are recrudescences.Malaria Journal 2006, 5:127 http://www.malariajournal.com/content/5/1/127
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not have recurrent infection. There is currently no consen-
sus on which approach should be taken, or the precise
modelling approach to the calculation of g.
Sample-size considerations
The assessment of efficacy of an antimalarial treatment is
based on the observed cure rate and the confidence inter-
vals around the estimate. In a comparison of two treat-
ments we calculate the individual confidence intervals
around the cure rates observed, then the difference
between the cure rates, and then the confidence interval
for the difference. The sample size determines the width
of these confidence intervals. Confidence interval calcula-
tions based on the normal approximation (for estimation
of the standard error) are not appropriate for very small
proportions (i.e. very low failure rates). The methods of
Wilson [17,18] and Newcombe [26] are preferable in the
case of a single proportion and multiple proportions
respectively.
Upper limits for 95% confidence intervals using Wilson's
method are presented in Figure 2 (solid line), for different
sample sizes and for treatment failure rates ranging
between 1 and 10%. Sample sizes of more than 150 give
an upper 95% confidence interval limit of less than 10%
when the observed failure rate is 5%. In the same figure
upper 95% confidence interval limits for the difference
between the observed cure rate of the new treatment and
the 95% cure rate of a standard treatment are presented
derived by Newcombe's methods.
The above calculations are based on the assumption that
there are no losses to follow-up. But if there are losses, the
'effective' sample size of Peto [12], which is defined later
in this paper, should be used in sample-size calculations.
As mentioned previously – the sample size should be cho-
sen on the basis of the estimated true cure rate. In all cal-
culations in this paper improved methods for confidence
intervals are presented (and recommended), as the stand-
ard methods based on the asymptotic normal approxima-
tion exhibit poor coverage, especially for small
proportions. Figure 5 illustrates the relationships between
sample size and power to detect superiority, and non-infe-
riority within the confines of cure rates between 90% and
100%.
Unequal randomization?
Unequal randomization, for example 2:1 randomization,
may also be considered in trials assessing new treatments.
Although unequal randomization sacrifices statistical
Table 2: Illustrating how the "Intention to treat" approach ascribing indeterminate treatment outcomes as failures overestimates the 
true failure rate. Low failure rate
Follow-up A (%) R = F(%) FITT (%) Overestimation of 
failure rate (%)
6 weeks 6 3 3.3 10%
8 weeks 20 5 6 20%
10 weeks 45 5 7.25 45%
12 weeks 68 5 8.4 68%
20 weeks 75 5 8.75 75%
If the failure rate is low (as it hopefully should be) the errors using the ITT approach are very large. In this example everything is the same as in the 
above example but now the true failure rate (F) is 5%,
A – cumulative probability of developing a patent new infection
R – cumulative probability of developing a patent recrudescence
Table 1: Illustrating how the "Intention to treat" approach ascribing indeterminate treatment outcomes as failures overestimates the 
true failure rate. High failure rate:
Follow-up A (%) R = F(%) FITT (%) Overestimation of 
failure rate (%)
6 weeks 6 15 15.3 2%
8 weeks 20 25 26 4%
10 weeks 45 25 27.25 9%
12 weeks 68 25 28.4 14%
20 weeks 75 25 28.75 15%
Assume that the entomological inoculation rate is 1/month (Figure 4), the true failure rate (F) is 25%, and 5% of PCR pairs are indeterminate. The 
patients are censored when a recurrent infection occurs.
Then at 4 weeks follow-up in the trial, the recurrence rate = 3.5% (2.5% true recrudescence, 1% true recurrence)
True failure rate = 2.5%, ITT analysis failure rate = 2.55%, overestimation 1.275%. FITT (%) = A + 0.05 R
A – cumulative probability of developing a patent new infection
R – cumulative probability of developing a patent recrudescenceMalaria Journal 2006, 5:127 http://www.malariajournal.com/content/5/1/127
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power slightly (or requires larger total sample size) in the
comparison, it increases the precision in the estimate of
treatment efficacy of the new drug, and it also provides a
better adverse-effect characterization for the new treat-
ment. The "control" (i.e. current treatment) trial arm is
still important in helping to distinguish "trial" from
"drug" problems i.e. it helps to identify systematic trial-
related confounders which lead to unusual efficacy or tox-
icity findings. For example, a trial in which non-inferiority
was shown but both treatment arms performed poorly
(i.e. less than 90% cure rates) would not warrant rejection
of the new treatment if the prior information suggested
much better efficacy of the established treatment. There
might have been a problem in the conduct of the trial.
Thus there is a statistical trade-off between both the char-
acterization of the difference between the two regimens
and the precision of the "control" arm estimate, and the
characterization of the new treatment effects. But there are
also biological and programmatic reasons why it may be
important to have a larger sample size for the new antima-
larial treatment; as cure rates asymptotically approach
100% the selective force that drives the emergence and
spread of resistance weakens, and in low transmission
areas, provided coverage is high, the incidence of malaria
will fall. Precise characterization of very high cure-rates
provides important information to the policy maker
which will be taken into account with costs, simplicity of
administration, tolerability, adverse effect profile, etc., to
influence the difficult decision of whether or not to
change treatment recommendations.
It is evident from Figures 2, 5, and 6 that large sample sizes
are required to provide sufficient precision when efficacy
is high. Maximum likelihood methods can be used to
adjust the balance of unequal samples to optimize the
information gained [31].
Practical realities
If the existing recommended antimalarial treatment used
in comparative assessments of new antimalarials is still
highly efficacious then sample sizes in conventional supe-
riority trials must be large. For example, if the true cure
rate for a new antimalarial treatment exceeds 99%, then
the total sample size required to show superiority over the
existing treatment, if this has an efficacy of 95%, exceeds
650. This doubles to over 1,300 if the new treatment is
98% efficacious. A 2:1 randomization increases these
numbers by <8%. Few single centre antimalarial drug tri-
als enrol more than 650 patients in a study. This seems to
be the limit for superiority testing. If a non-inferiority trial
is conducted, and the differences are much larger than
anticipated, then a significant difference may be demon-
The relationship between sample size (in a single sample) and  precision in characterizing the cure rate is shown; the upper  solid line shows the boundary for the cure rate below which  the lower 95% confidence interval bound for the proportion  falls below 90%, and the lower dotted line shows the bound- ary for the cure rate below which the upper 95% confidence  interval bound for the proportion exceeds 90% Figure 6
The relationship between sample size (in a single sample) and 
precision in characterizing the cure rate is shown; the upper 
solid line shows the boundary for the cure rate below which 
the lower 95% confidence interval bound for the proportion 
falls below 90%, and the lower dotted line shows the bound-
ary for the cure rate below which the upper 95% confidence 
interval bound for the proportion exceeds 90%. Sample sizes 
to the left of the curves provide inadequate precision if the 
objective is to be sure the confidence interval for the sample 
does not cross 90%.
 10
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Single sample
Cure rate (%)
Inadequate precision
Operating within the confines of cure rates which should  exceed 90%, and thus trials which must have the statistical  power to exclude, with 95% confidence, that the cure rate of  the new antimalarial does exceed this value, the relationship  between sample size (y axis) and cure rate of the established  treatment (x axis) is illustrated Figure 5
Operating within the confines of cure rates which should 
exceed 90%, and thus trials which must have the statistical 
power to exclude, with 95% confidence, that the cure rate of 
the new antimalarial does exceed this value, the relationship 
between sample size (y axis) and cure rate of the established 
treatment (x axis) is illustrated. For superiority trials with 
2α= 0.05 and β = 0.2, the dashed line shows the lower limit 
of possible sample sizes; i.e. when the new treatment has an 
estimated efficacy of 100%. For non-inferiority trials the solid 
line shows the sample size required to ensure that the 95% 
CI for treatment efficacy of the new treatment exceeds 90%; 
i.e. the non-inferiority margin δ is (cure rate of the standard 
treatment-0.9), assuming that the true cure rates are the 
same. These assume 1:1 randomization.
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strated. If the new compound has a significantly lower
cure rate this would argue against its introduction. For the
established compound more investigation might be nec-
essary to determine the reasons why it performed less well
than expected.
Discussion
The outlook for antimalarial chemotherapy has improved
in recent years with the introduction of several new highly
effective drug combinations, and elevation in the cure
rates now required of these new treatments. A cure rate of
at least 90% in uncomplicated malaria assessed at 28 days
is recommended by the World Health Organization [1].
As a result antimalarial drug evaluations will increasingly
be performed with highly effective current treatments as
comparators. This makes the sample-size requirements for
conventional superiority trials logistically difficult or sim-
ply impossible (Figure 5). Furthermore, demonstration of
superiority by a small margin (by definition only a few
percentage points), although potentially important in
terms of resistance prevention, may be offset in opera-
tional terms by unrelated factors such as cost, simplicity of
dosing, or adverse effects profile. It is worth noting that
cure rate targets in drug development (i.e. phase 3) can be
lower than in operational use, as there may still be
improvements possible (particularly in dosing) which
would increase the cure rate. But once the drug formula-
tion and dosing have been optimized cure rates should
ideally exceed 95%, and showing superiority within the
95 to 100% cure rate range is unlikely to be logistically
feasible. Non-inferiority trials are alternatives to superior-
ity trials which provide valuable information, but require
a different approach to sample-size calculations, and are
very vulnerable to confounders introduced by poor con-
duct of the study. As antimalarial drug trials employ
longer follow-up periods to characterize better antimalar-
ial drug efficacy, the problems with missing or indetermi-
nate data will increase. Incorrect analysis of these data
(particularly calling all missing or indeterminate results
"failures") may lead to significant overestimates of treat-
ment failure rates, and could even lead to inappropriate
discontinuance of an effective treatment. Standardizing
analytical approaches is as important as standardizing
clinical trial methodology. The intention to treat (ITT)
approach to analysis of efficacy, which treats patients with
incomplete follow-up and other protocol deviations as
treatment failures, is widely recommended as it provides
the most conservative estimates of efficacy, and thereby
reduces the possibility that bias may favour one of the
treatments. The ITT analysis should be reported in com-
parative trials of antimalarial drugs, as it gives an unbiased
assessment of differences and provides a comparison of
effectiveness and toxicity leading to trial discontinuation,
but it should not be the primary end-point used as a basis
for sample-size calculations, or for reporting efficacy
assessments in uncomplicated malaria. This is because
practitioners and policy makers need to know true failure
rates, and at the low failure rates now required of new
antimalarial drugs, the ITT analysis considerably overesti-
mates the true failure rate if there are patients who do not
complete the study (Figure 3). Effectiveness is certainly
the most important parameter in assessing antimalarial
drugs, but to interpret ineffectiveness it is necessary to
know efficacy. Omitting patients with incomplete follow-
up from the denominator in failure rate estimates also
leads to significant overestimates, particularly if the
majority of failures occur early in a trial. In non-inferiority
trials where there are protocol deviations and incomplete
follow-up the ITT approach may lead to a false conclusion
of non-inferiority. To estimate antimalarial drug efficacy
the survival analysis approach provides the best compara-
tive estimates of therapeutic efficacy. It is well established
in non-infectious diseases, and should be used more in
the assessment of all infectious disease treatments where
the assessment of treatment failure rates requires long fol-
low-up.
There has been a considerable improvement in the quality
and quantity of antimalarial drug trials reported in recent
years. The introduction of PCR genotyping [8] has
allowed large community based studies to be conducted
in patients of all ages. In the low-transmission settings
where it was first used there have been relatively few prob-
lems with interpretation. But at high levels of transmis-
sion intensity multiple genotypes are usual and without
quantitative methods, it may be difficult or impossible to
ascribe genotypes accurately [32]. Better genotyping
methods are being developed but, for the present, most
investigators rely on simple PCR with analysis of bands on
gel electrophoresis. This uncertainty, which makes confi-
dent distinction of a recrudescence and reinfection diffi-
cult or impossible, has led some investigators to suggest
that for trials in high transmission areas, genotyping
should be abandoned – arguing that reinfection and
recrudescence are of equal importance. This remains to be
proved. Such an approach would require a fundamental
change in the perspective on treatment (placing much
greater weight on post-treatment prophylactic effect). In
an artemisinin based combination treatment resistance to
the slowly eliminated partner drug will reduce the average
duration of the post-treatment prophylactic effect and
increase the probability of recrudescence. The relationship
between these two related effects depends on several inde-
pendent variables, and has not been well characterized for
any antimalarial drug. But while the jury remains out on
the relative importance of curative efficacy and the post-
treatment prophylactic effect, and more evidence is
accrued, treatment trials generally include genotyping –
and therefore will provide indeterminate or missing PCR
results. The ITT approach to analysis where all missing orMalaria Journal 2006, 5:127 http://www.malariajournal.com/content/5/1/127
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indeterminate PCR results are treated as failures, although
often undertaken, is obviously wrong. The longer the fol-
low-up, the greater are the chances of reinfection, and the
more PCR genotyping will be required. This will produce
correspondingly more indeterminate or lost results and
greater overestimation of the true failure rate – all of
which is independent of drug efficacy. There are two pos-
sible approaches to resolve the problems this creates;
either these patients should be omitted from the calcula-
tions (this preserves the correct difference between the
groups but gives imprecise individual drug efficacy esti-
mates), or preferably if there are sufficient data then a sur-
vival analysis approach should be taken, and the time
adjusted probabilities of recrudescence versus reinfection
should be calculated from the valid genotyping pairs.
Thus a data driven probability can be ascribed at any time
point to a recurrent infection being a recrudescence. Both
approaches are compromised if patients who "drop out"
from trials or have missing or indeterminate PCR values
are unrepresentative of the remaining patients (i.e. they
are more or less likely to fail treatment than the rest). This
will need to be evaluated locally. The greater the number
of missing values the less confidence there will be in the
results of the trial. Standardization of methodologies and
consensus recommendations on analytical approaches
would help the malaria researchers and control pro-
grammes.
With the increasing efficacy of new treatments and
requirement to aim for cure rates of > 90% and preferably
≥ 95%, comparative trials should generally be designed as
non-inferiority trials in which the null hypothesis is that
there is a difference between the two groups when existing
treatment efficacy still exceeds 95%. These trials should be
powered to give a predefined precision for estimates of
cure rates. For consideration as a policy option the point
estimate of the cure rate of the new drug treatment, and
the currently recommended treatment should both exceed
90% as this is the threshold currently recommended by
WHO. Large trials are required to provide adequate preci-
sion of these estimates.
Conclusion
Antimalarial drug comparisons must be large enough to
provide precise cure-rate estimates, and follow-up must be
long enough to capture the majority of recrudescences.
Non-inferiority trials may be necessary when standard
treatment efficacy is high (cure rates over 90%), but these
have weaknesses which may not be familiar to investiga-
tors used to superiority trials. The primary efficacy end-
point should be derived from survival analysis. Intention
to treat and per protocol point-analyses should be
reported also as secondary results. The interpretation of
current PCR gel-electrophoresis derived genotyping
results in high transmission settings is difficult. Indetermi-
nate or missing results should not be classified as treat-
ment failures, but should also analysed using a survival
approach. Consensus recommendations on the interpre-
tation and analysis of antimalarial drug trials would be of
great benefit.
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ori – number of observed recurrences at time ti
PCR polymerase chain reaction
p – proportion of subjects beyond any follow-up time t
who have not developed a recrudescence
PP – "per protocol" analysis
R – cumulative probability of developing a patent recru-
descence
ri – patients with recrudescent infections at time ti
t1/2 – antimalarial drug elimination half life
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Appendix 1
Example: Analysing a non-inferiority trial
In a study, patients were randomly assigned treatment A
or B and were followed up for 63 days. The aim of the
study was to show that the new treatment (A) is not less
effective than the standard treatment (B). A priori a margin
of clinical non-inferiority (δ) had to be selected, which is
defined as the largest reduction in efficacy which would be
clinically acceptable.
As we are interested in non-inferiority of treatment A, the
95% CI for the difference in efficacy (A-B) should be less
than the value – δ.
In this example a δ of 0.1 (i.e. 10%) was selected. There
were 100 patients in each group. For those who were lost
to follow-up or had a recurrence of infection we list the
length of follow-up completed in the table below. Stars
denote loss to follow-up. In treatment group A six failures
were observed and six patients were lost to follow-up,
while in group B four failures were observed and three
patient were lost to follow-up.
A; 14* 14* 22  22 * 28* 28* 28* 34 44 52 61 63
B; 14* 14* 17  24   28*  29   43
Using the Kaplan-Meier method we estimate the efficacy
as 0.94 (0.86 to 0.97) for treatment A and 0.96 (0.89 to
0.98) for treatment B.
The difference in efficacy (absolute risk reduction) A-B is -
0.02. To calculate the confidence interval around this dif-
ference we need to calculate the 'effective' sample sizes: nA
= 88/0.94 = 94 and nB = 93/0.96 = 97. Using Newcombe's
formula we obtain a 95% CI for the difference of (-0.09 to
0.05).
As the confidence interval is more positive than the δ of
– 0.1 we conclude that treatment A is not inferior to
treatment B. But it should be noted that even with 100
patients per group the trial is underpowered; the precision
of the cure rate estimates is poor (both confidence inter-
vals for the individual group cure rates cross the 90%
boundary) – see Figure 5.
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